Navigation Links
The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results
Date:7/16/2008

Survey Highlights Trends In eCTD Migration And Submissions Outsourcing And Provides Insights Into Regulatory Product Management Trends Across North

America And Europe

PHILADELPHIA and LONDON, July 17 /PRNewswire/ -- The Scientific business of Thomson Reuters today announced the early findings of its 2008 Liquent Regulatory Affairs Trends Survey. The survey attracted respondents from across the globe representing small, medium and large pharmaceutical companies and provides a unique insight into emerging and future trends in regulatory product management usage and adoption.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NYTH069LOGO )

Now in its sixth year and frequently sourced by pharmaceutical journals and publications across the world, this survey has become the premier benchmark of global regulatory submission trends offering timely insights into how pharmaceutical regulatory professionals use technology today and how they plan to harness technology in the future.

There were 137 Regulatory Affairs professionals working in Life Sciences companies across the globe who participated in this survey. The survey concentrates on four key areas: Technology Usage Trends, including both submission publishing software and other desktop software, Document Management System usage, Regulatory Outsourcing trends, and Regulatory trends including use or future use of the electronic Common Technical Document (eCTD).

The demographic make-up of the respondent population is similar to previous years with almost one third working in large pharmaceutical companies (32%) and more than a third working in small to medium companies (36%). Another 10% of respondents work for biotechnology companies. There were significantly more respondents from Contract Research Organizations (CROs) in 2008 (10%) than in 2007 (4%). 68% of those sur
'/>"/>

SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Principle of Recursive Genome Function Supersedes Dogmas; By Andras Pellionisz, Online Ahead of Print; (Scientific Visionary Vindicated)
2. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
3. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
4. ISMPP Applauds AAMC Clarification on Ghostwriting Versus Transparent Writing Collaboration in Scientific Publications
5. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
6. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
7. Boston Scientific To Webcast Conference Call Discussing Second Quarter Financial Results
8. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
9. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
10. Californias International Stem Cell Collaborations Must Be Based on Scientific Merit, Consumer Group Says
11. Corgenix Expands Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 This research report ... Starch Based Plastics, Regenerated Cellulose, PCL), by Application ... and Forecasts to 2019”, defines and segments the ... forecast of its global volume and value. , ... spread through 178 Slides and in-depth TOC on ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in ... announced that its Board of Directors has appointed ... President and member of the Board effective immediately. ... expanded responsibilities within the company, including further developing ... commercialization, manufacturing and finance. , Dr. Carol ...
(Date:10/25/2014)... Great Barrington, MA (PRWEB) October 25, 2014 ... contamination control products, is pleased to announce the ... to achieve the highest level of contamination containment ... in ISO Class 3 and higher cleanroom environments, ... continuous filament polyester knit laundered wiper that continues ...
(Date:10/25/2014)... NEW YORK , Oct. 24, 2014 ... Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical company advancing ... implemented a 1-for-50 reverse split of its common ... Friday, October 24, 2014. PlasmaTech,s common stock will ... number 72754H109 and temporary ticker symbol "ACCPD". After ...
Breaking Biology Technology:Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2
... April 8 ImQuest Life Sciences presented their ... their novel small molecule piperazine compound for the ... Therapeutics meeting held in Whistler, British Columbia. The ... lead microtubule inhibitor, IQP-0304. The piperazines demonstrate potent ...
... 8 Micromet, Inc. (Nasdaq: MITI ... for the treatment of cancer, inflammation and autoimmune ... the peer-reviewed Journal of Immunotherapy (1) demonstrating the ... to carcinoembryonic antigen (CEA) and to CD3 on ...
... 7 Pharmatech Oncology, Inc., a Research Management Organization ... companies at the Company Showcase during BIOZONA 2009 - ... Downtown on April 7th in Phoenix, Arizona.Matthew B. Wiener, ... during the first session of the conference. The ...
Cached Biology Technology:ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program 2Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 2Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 3Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 4Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA 2
(Date:10/22/2014)... by Northwestern Medicine® scientists helps explain how bipolar disorder ... new drug therapies to treat the mental illness. ... the same method recognized with the 2014 Nobel ... brain tissue from mice with bipolar-like behaviors. In the ... tiny "nanodomain" structures with concentrated levels of ANK3 -- ...
(Date:10/18/2014)... and stress-related psychiatric disorders are associated with ... molecular mechanisms underlying this relation are unknown. ... development of targeted preventive strategies and new ... This work is presented at the European ... an international group of researchers from Germany ...
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... million years ago, when the lineage of humans and ... turnips may have been one of the reasons. According ... of Minnesota and Richard Wrangham of Harvard University, the ... tubers must have sustained our ancestors who left the ...
... all likely to blame for poisoning the waters being drained from ... is leaving behind -- also owes its contamination to a source ... environments that made their way en masse into the water as ... Florida professor who has spent years studying the harmful contaminants that ...
... other non-terminal, debilitating conditions and diseases is both feasible ... such test on the approach in patients with advanced ... edition of the Proceedings of the National Academy of ... the potential to block the destructive inflammation process that ...
Cached Biology News:The roots of civilization trace back to ... roots 2Toxic flood lifts lid on common urban pollution problem 2Toxic flood lifts lid on common urban pollution problem 3Results of world's first gene therapy trial for arthritis show approach safe, feasible 2Results of world's first gene therapy trial for arthritis show approach safe, feasible 3Results of world's first gene therapy trial for arthritis show approach safe, feasible 4
MAb to Vasopressin Preservative: NaN3...
... Anti-AP-2 α, clone 8G8/5 GenBank Accession ... made human AP-2alpha/gamma fusion protein corresponding to ... 278-450 of human AP-2γ Formulation: 0.1M Tris-glycine, ... before the addition of glycerol to 30% ...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
Biology Products: